 Physician & Payer Forum --
August 2007
 In This Issue...
Oral tyrosine
kinase inhibitors (TKIs) achieved more than $3.5 billion in sales in 2006. In
the last three years, four new oral TKIs have launched, and several more,
including AstraZeneca’s Zactima (vandetanib), are in late stages of
development. Oral TKIs offer patients a well-tolerated, conveniently
administered alternative to intravenous (IV) therapy and account for a large
portion of the targeted cancer therapies market, and their use is increasing.
Decision Resources’ Physician&PayerForum report, "How Are New and Emerging Oral Tyrosine
Kinase Inhibitors Threatening Established Anticancer Agents?" explores how new
oral TKIs are fitting into the targeted cancer therapies market and examines
what threat they pose to established targeted and non-targeted therapies.
We surveyed 100 oncologists and 20 MCO pharmacy directors (PDs) and compared their
responses to assess similarities and differences. This survey enabled Decision
Resources to achieve the following:
- Understand what the main factors are that encourage and limit oncologists’
prescribing of oral TKIs.
-Reveal how
oncologists believe their prescribing of available TKIs will evolve over
the next 12 months.
-Uncover how
oncologists are using available TKIs. Do they limit prescribing of Tarceva
(Genentech/Osi’s erlotinib) to patients with positive predictive factors
for response? Do they prescribe Tykerb (GlaxoSmithKline’s lapatinib) to
patients at risk of brain metastases?
-Understand
how Tykerb will fare if it is approved in combination with a taxane for
the first-line treatment of breast cancer?
-Understand how
financial incentives impacting U.S. oncologists will impact prescribing of
oral TKIs, particularly when the TKIs compete with intravenously
administered agents.
-Discover how
patient out-of-pocket costs impacts uptake of oral TKIs.
-Discover
whether MCOs are developing pay-for-performance systems for oncologists.
-Discover
how MCO PDs perceive the relative cost-effectiveness of oral TKIs in
relation to their IV competitors.
|
